TrialThe New England journal of medicine2019
Trastuzumab Emtansine for Residual Invasive HER2-Positive Breast Cancer.
Gunter von Minckwitz et al.PubMed ↗Publisher ↗
No numbers read from the abstract.
1,244 papers cite itlatest 60 shown
this paperpooled ittrialcites it